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Background. The relationship between C-reactive protein (CRP) elevation and ventricular tachycardia (VT) in arrhythmogenic
right ventricular dysplasia/cardiomyopathy (ARVD/C) is unclear. Methods and Results. In 91 consecutive patients with either
ARVD/C with or without VT (cases) or idiopathic right ventricular outﬂow tract (RVOT) tachycardia (controls), blood sampling
were taken to determine CRP levels. In ARVD/C patients with VT, we analyzed the association between VT occurrences and
CRP level. Sixty patients had ARVD/C, and 31 had idiopathic RVOT VT. Patients with ARVD/C had a signiﬁcant higher level of
CRP compared to those with RVOT VT (3.5 ± 4.9v e r s u s1 .1 ± 1.2mg/l,P = .0004). In ARVD/C group, 77%, (n = 46) patients
experienced VT.Ofthese, 37% (n = 17) underwent bloodtestingforCRPwithin24hafter theonsetof VTandtheremaining63%
(n = 29) after 24h of VT reduction. CRP level was similar in ARVD/C patients with or without documented VT (3.6 ± 5.1mg/l
versus 3.1 ± 4.1mg/l,P = .372). However, in patients with ARVD/C and documented VT, CRP was signiﬁcantly higher when
measured within 24 hours following VT in comparison to that level when measured after 24h (4.9±6.2mg/lversus3.0±4.4mg/l,
P = .049). Conclusion. Inﬂammatory state is an active process in patients with ARVD/C. Moreover, there is a higher level of CRP
in patients soon after ventricular tachycardia, and this probably tends to decrease after the event.
1.Introduction
Ventricular arrhythmias are a common ﬁnding with related
poor outcomes in the setting of cardiomyopathies, either
structural or electrical. Arrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C) is a primary heart
muscle disease characterized by progressive atrophy of the
right (but also left) ventricular myocardium with ﬁbro-
fatty replacement and the risk of electrical instability and
sudden death [1–3]. The disease is often familial, and
the pathophysiology is still unknown. Many studies have
shown that ARVD/C implicates an inﬂammatory pathway
with foci inﬁltrates with T lymphocytes cells in biopsy
materials [4]. Whether inﬂammatory activity expressed by
CRP concentration may play a role in pathogenesis of
arrhythmias of ARVD/C has been little studied.
Our study ﬁrst evaluated the inﬂammatory activity
expressed by CRP concentration in patients with ARVD/C.
Secondly,weassessedtheassociationbetweenVToccurrence
and CRP levels. Finally, we examined the temporal associa-
tion between VT onset and CRP level (< or >24 hours).
The study group was compared to patients with similar
features of ventricular arrhythmias arising from right ventri-
cle.2 Cardiology Research and Practice
2. Methods
2.1. Study Population. Enrollment took place from October
2001toMarch2008inHopitalPitieSalpitriere,Paris,France.
The study population consisted of 105 consecutive patients.
These patients were referred for ARVD/C screening based
on right ventricular ectopic beats, right ventricular tachy-
cardia, or family history of inherited arrhythmic disorder or
sudden unexplained death. We reviewed their past medical
histories and carried out a complete physical examination
on all patients. All patients were subjected to cardiac tests
(12-lead ECG, 24-hour ECG monitoring, signal averaged
ECG, 2-D echocardiography, exercise ECG testing, coronary
angiography, left and right ventricular contrast angiography
and/or ventricular radionuclide imaging, and/or cardiac
MRI) and blood sampled for CRP testing. The diagnosis
of ARVD/C was according to the guidelines published by
the Working Group of Myocardial and Pericardial Diseases
of the European Society of Cardiology and the Scientiﬁc
Council on Cardiomyopathies of the International Society
and Federation of Cardiology [5]. This classiﬁcation takes
account of genetics, electrocardiographic depolarization and
repolarization, and arrhythmic, structural, and histological
factors.Basedonthisclassiﬁcation,thediagnosisofARVD/C
requires the presence of two major criteria, one major and
two minor criteria, or four minor criteria. Right ventricular
function is considered abnormal if right ventricular ejection
fraction (RVEF) was less than 45%. Diagnosis of RVOT VT
wasbasedonstandardguidelines[6].Patientswithsuspected
infection/inﬂammatory process during the screening were
excluded from the study (n = 14). When CRP concentration
was >10mg/l, we particularly attempted to ﬁnd any known
cause. Indeed for each of these patients exhaustive diagnostic
tests were performed to rule out a systemic infection (white
cell account, urinary test, and chest X-ray) or other sec-
ondarycausesofCRPelevationsuchasthrombosisorcancer.
In patients with CRP >10mg/l (4 patients), additional check
up with body CT scan for tumor diagnosis or systemic
inﬂammationwasperformed.Wealsoexcludedpatientswith
recent (<1 week) electrical cardioversion, either external or
by ICD.
2.2. Ventricular Arrhythmia Diagnosis. Premature ventricu-
lar contraction (PVC) was deﬁned as wide ectopic beat with
no anterograde P wave and sometimes retrograde P wave.
More than 3 consecutive PVCs were classiﬁed as VT and sus-
tained VT sought to last >30 sec. Wide complex tachycardia
was diﬀerentiated between supraventricular tachycardia with
conduction aberrancy and VT using Vereckei algorithm [7].
We diagnosed ventricular arrhythmia (VA) using resting 12-
lead ECG (Figure 1), ambulatory holter monitoring, anal-
ysis of implantable cardioverter-deﬁbrillator (ICD) storage
electrogram, or analysis of automated external deﬁbrillator
(AED) during rescue.
2.3. Blood Testing. On admission, before any invasive inter-
vention, all patients underwent blood testing for C-reactive
protein concentration using immunoturbidimetric Integra
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Figure 1: ECG of patient with ARVD/C and VT. A 32-year-old
female with recurrent episodes of palpitation and near-syncope was
admitted in ICU. Resting 12-lead ECG showed VT (wide complex
tachycardia with capture) with rate of 150/min. SR was restored
with bolus dose (600mg during 1min) of amiodarone. Blood
samplingforCRPwasdrawn immediatelyafteradmission.Detailed
examination led to the diagnosis of ARVD/C with family (brother)
inheritance. ICU, Intensive care unit; VT, Ventricular tachycardia;
CRP, C-reactive protein; SR, Sinus rhythm.
400 Roche method. The time lapse between the last docu-
mentedspontaneousVTeventandbloodsampling(VT/CRP
< 24h and VT/CRP > 24h) was also recorded. We used only
CRP measurements for characterization of inﬂammation.
2.4. Statistical Analysis. Continuous variables are expressed
as mean ± SD and statistical signiﬁcance was assessed
using the unpaired Student’s t test or Mann-Whitney U test
where applicable. Categorical variables, were summarized
as proportion, and compared using the chi-square test or
Fischer’s exact test. The correlation between CRP levels
and the rate of VT was assessed using Pearson correlation
coeﬃcient. Logistic regression was used to assess strength
of association. In the multivariate model, only factors that
attained statistical signiﬁcance (P<. 1) in the univariate
analysis were included. The χ2 test with a 2-tailed P value <
.05 was considered statistically signiﬁcant. Statistical analysis
was performed with SPSS version 11.0.1 software (SPSS Inc).
3. Results
3.1. Characteristics of the Baseline Population. Our study
sample included 91 patients. The baseline characteristics of
our population are shown in Table 1. The mean age of the
study population was 39 ± 13 years with 73% being male.
The prevalence of cardiovascular risk factors was low: 4%
hypertension, 14% smokers, 8% hypercholesterolemia, and
none were diabetic. Figure 2 shows the distribution of the
study population by ARVD/C, VT occurrence, and CRP
measurement timing from VT occurrence.
3.2. Comparison of Patients with ARVD/C and RVOT
Tachycardia. Sixty patients had ARVD/C, and 31 patients
had RVOT tachycardia. Their characteristics are shown on
Table 1. Study populations were similar in age distribution,Cardiology Research and Practice 3
Table 1: Baseline characteristics of patients with ARVD/C and
RVOT tachycardia.
ARVD/C
(n = 60)
Mean ± SD
RVOT
tachycardia
(n = 31)
Mean ± SD
P value
Age (years) 39 ± 14 38 ± 12 .631
Male (%) 85 48 .0002
Hypertension (%) 8 0 .123
Hypercholesterolemia (%) 4 12 .209
Smokers (%) 17 19 .871
RV dysfunction (%) 23 0 .004
Statin (%) 5 0 .206
Aspirin (%) 3 3 .978
Documented VT (%) 77 100 .037
VT-R 195 ± 46 182 ± 41 .374
ICD 38 10 .006
CRP measured <24h
following VT (%) 37 34 .864
ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy;
RVOT, Right ventricular outﬂow tract; RV, Right ventricular; VT, Ven-
tricular tachycardia; VT-R, Ventricular tachycardia rate; ICD, Implantable
cardioverter-deﬁbrillator; CRP, C-reactive protein.
Study population : n = 91
Patients with begnin
RVOT arrhythmia:
N = 31
Patients with documented
ARVD/C: N = 60
VT+
N = 46
VT−
N = 14
CRP measured
< 24h after VT
N = 17
CRP measured
> 24h after VT
N = 29
Figure 2: Flowchart of study population. Study population
included case group (ARVD/C) and control (RVOT ). Among 60
ARVD/C patients, 46 had VT of whom 17 underwent CRP testing
less than 24h after VT occurrence. ARVD/C, Arrhythmogenic right
ventriculartachycardia;RVOT,Rightventricularoutﬂowtract;CRP,
C-reactive protein; VT, Ventricular tachycardia.
history of hypertension, dyslipidemia, smoking, statin and
aspirinuse.HoweverpatientswithARVDweremorelikelyto
bemale(85%versus48%,P<. 05)andhaverightventricular
dysfunction (23% versus 0%, P = .004) to patients to
RVOT tachycardia. While all patients in the control group
experienced VT, only forty six (77%) ARVD/C patients
experienced it (P = .037). Nineteen (32%) ARVD/C patients
hadICDbeforeinclusionwhereasnoneoftheRVOTpatients
had ICDs. Finally as shown in Figure 3, the mean CRP level
was 3.5 ± 4 . 9m g / li nA R V D / Cg r o u pa n d1 . 1± 1.2mg/l in
the control group (P = .009).
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Figure 3: CRP levels of patients ARVD/C and RVOT tachycardia.
ComparisonofCRPconcentrationsbetweenpatientswithARVD/C
(case) and RVOT tachycardia (control). CRP, C-reactive protein;
ARVD/C, Arrhythmogenic right ventricular dysplasia/tachycardia;
RVOT, Right ventricular outﬂow tract.
Table 2: Multivariate analysis∗ in patients with ARVD/C or RVOT
tachycardia.
P value 95% Conﬁdence interval
Male (%) .024 1.19–11.85
RV dysfunction (%) .977 0.005–0.008
Documented VT (%) .718 0.24–2.67
ICD .712 0.26–6.97
CRP concentration .025 1.07–2.78
ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy;
RVOT, Right ventricular outﬂow tract; RV, Right ventricular; VT, Ven-
tricular tachycardia; VT-R, Ventricular tachycardia rate; ICD, Implantable
cardioverter-deﬁbrillator; CRP, C-reactive protein.
Table 3: Characteristics of ventricular arrhythmias of overall
population.
Diagnostic tools Heart rate
R. ECG E. testing A. ECG ICD/AED ARVD/C RVOT P
42 (63%) 7 (10%) 7 (10%) 13 (19%) 195 ± 46 182 ± 41 .374
ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy;
RVOT, Right ventricular outﬂow tract; RV, Right ventricular; VT, Ven-
tricular tachycardia; VT-R, Ventricular tachycardia rate; ICD, Implantable
cardioverter-deﬁbrillator; CRP, C-reactive protein.
Table 2 shows the multivariate analysis. Only the male
sex, CRP level and spontaneous VT were independently
associated with ARVD/C.
3.3. Ventricular Arrhythmia Features of Overall Population.
The characteristics of VA of our study population are shown
in Table 3. There was no correlation between VT rate and
CRP levels (r = 0.09; P = .542). CRP levels were similar
in patients with or without clinical manifestations (syncope
or aborted sudden cardiac death) due to VA (P = .886).4 Cardiology Research and Practice
Table 4: Baseline characteristics of ARVD/C patients with or
without documented VT.
VT+
(n = 46)
Mean ± SD
VT−
(n = 14)
Mean ± SD
P value
Age (years) 40 ± 15 38 ± 8 .641
Male (%) 87 79 .423
Hypertension (%) 11 0 .561
Hypercholesterolemia (%) 16 0 .313
Smokers (%) 14 27 .367
RV dysfunction (%) 24 21 .998
Statin (%) 7 0 .998
Aspirin (%) 4 0 .998
CRP level (mg/L) 3.6 ± 5.1 3.1 ± 4.1 .372
ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy;
RVOT, Right ventricular outﬂow tract; RV, Right ventricular; VT, Ven-
tricular tachycardia; VT-R, Ventricular tachycardia rate; ICD, Implantable
cardioverter-deﬁbrillator; CRP, C-reactive protein.
Table 5: Baseline characteristics of ARVD/C and documented VT
patients with or without CRP level measured within the 24 hours
following VT.
CRP < 24h
(n = 17)
Mean ± SD
CRP > 24h
(n = 29)
Mean ± SD
P value
Age (years) 44 ± 18 37 ± 13 .196
Male (%) 88 86 .998
Hypertension (%) 20 45 .283
Hypercholesterolemia (%) 27 9 .198
Smokers (%) 20 10 .630
RV dysfunction (%) 31 21 .698
Statin (%) 12 3 .285
Aspirin (%) 6 3 .998
VT-R 188 ± 41/min 201 ± 51/min .552
ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy;
RVOT, Right ventricular outﬂow tract; RV, Right ventricular; VT, Ven-
tricular tachycardia; VT-R, Ventricular tachycardia rate; ICD, Implantable
cardioverter-deﬁbrillator; CRP, C-reactive protein.
3.4. Comparison between ARVD/C Patients with and without
VT. In the ARVD/C group, 46 (77%) patients had at
least one documented spontaneous episode of VT (>3
consecutives PVC). The comparison between ARVD/C with
and without VT is shown in Table 4.T h eo c c u r r e n c eo f
VT was not related to structural changes in the right
ventricle. Indeed, RV dysfunction (RVEF < 40%) assessing
by imaging techniques (2-D echocardiogram, radionuclide
ventriculography, cardiac MRI or ventricular angiography)
was similar in patients with or without VT (24% versus
21% resp., P = .99). CRP concentrations did not diﬀer
signiﬁcantly with respect to previous history of VT (VT+
versus VT−). The mean CRP levels in the VT and no-VT
subgroups were 3.6 ± 5.1 and 3.1 ± 4.1mg/l (P = .372),
respectively.
0
1
2
3
4
5
6
C
R
P
l
e
v
e
l
(
m
g
/
L
)
CRP < 24h CRP > 24h
P = .049
Figure 4: CRP level in patients with ARVD/C and VT according
to the timing between CRP measurement and VT occurrence (<
or >24h). CRP concentration of ARVD/C patient with the history
of VT was signiﬁcantly greater when blood work-up for CRP was
drawn within 24h of VT onset compared to the time lapse >24h
after VT restoration of SR. CRP, C-reactive protein; ARVD/C,
Arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT,
Ventricular tachycardia; SR, Sinus rhythm.
3.5. Comparison of ARVD/C Patients with VT According to
CRP Timing Measurement. Of 46 ARVD/C patients with
VT, blood testing for CRP measurement was performed
within 24h after VT occurrence (CRP/VT < 24h) in 17
(37%) patients. Both subgroups were similar regarding
cardiovascularrisk factors, right ventricular contractility and
ventricular rate during VT (Table 5). As shown in Figure 4,
CRP levels were signiﬁcantly higher when measured in less
than 24h after VT occurrence (4.9 ± 6.2mg/l versus 3.0 ±
4.4mg/l, P = .049).
4. Discussion
4.1. Major Findings. This study shows that ARVD/C is
associated with inﬂammation, as indicated by higher CRP
concentration. The inﬂammatory state is similar in all
ARVD/C patients, regardless of the history of ventricular
tachyarrhythmia. CRP levels were signiﬁcantly higher when
blood sampling was performed in the ﬁrst 24 hours of VT
manifestation.
4.2. Inﬂammation and Cardiovascular Outcomes. C-reactive
protein is a biomarker of inﬂammation and its increase
level predicts cardiovascular events such as stroke, coronary
heart disease, or peripheral vascular disease [8, 9]. Serum
CRP level greater than 2mg/l has been shown to predict
theses cardiovascular events [10] and anti-inﬂammatory
agents such as statins have demonstrated a reduction of
cardiovascularmortality in patients with normal lipid proﬁle
[11].
It is known that systemic inﬂammation is associated
with arrhythmia occurrence. This association has clearly
been established during atrial ﬁbrillation (AF). It has been
shown that increased CRP levels are associated with greater
risk of AF recurrence after electrical cardioversion [12].
Moreover, dilated cardiomyopathy patients with AF have
higher inﬂammation activation than those without AF [13].Cardiology Research and Practice 5
Ventricular arrhythmia (VA) occurrence is associated
with signiﬁcantly elevated proinﬂammatory markers such
as IL-6 and highly sensitive C-reactive protein (hs-CRP) in
implantable cardioverter-deﬁbrillator (ICD) patients with
structural heart disease [14]. Additionally, during acute
myocardial ischemia, patients with malignant VA experience
higher systemic inﬂammation activation than those without
VA [15].
Myocardial inﬂammation seems to play an important
role in chronic heart failure and cardiomyopathies. Despite
all reports, a clear correlation with clinical outcome and
survival rates has not been documented and clinical studies
have not shown consistent beneﬁcial eﬀects of an anti-
inﬂammatory therapy [16–18].
Enhanced inﬂammatory response is related to the devel-
opment of ventricular tachycardia or ventricular ﬁbrillation
(VT/VF) after ST-elevation myocardial infarction (STEMI)
[19]. Consistent with the later, statins which have anti-
inﬂammatory properties [20] are associated with decreased
incidence of ventricular tachycardia (VT) [21–24]. However,
recentdatahassuggestedthatinﬂammatorybiomarkerssuch
as IL-6, TNF-alpha, hsCRP, and BNP are not predictive of
intermediate-term risk of ventricular tachyarrhythmias in
stable chronic heart failure [25].
Finally, whether the activation of systemic inﬂammation
is the cause or the consequence of ventricular arrhythmias is
unknown.
4.3. Inﬂammation during ARVD/C and Its Relationship
with VT Occurrence. As demonstrated in previous studies,
the risk proﬁle which emerges from retrospective analysis
of clinical and pathologic series, including fatal cases, is
characterisedbyyoungage,competitivesportactivity,malig-
nant family background, extensive right ventricular disease
with low ejection fraction and left ventricular involvement,
syncope, and episodes of complex ventricular arrhythmias
[3, 26].
Previous studies have found foci inﬁltrates with T
lymphocytes cells in biopsy materials of patients with
ARVD/C [27–32]. Therefore, ARVD/C may be considered
as an appropriate model to study the relationship between
inﬂammation and ventricular arrhythmia which is a major
clinical feature of this inherited arrhythmogenic disease.
Consistent with this, we found that the baseline CRP level
was signiﬁcantly higher in patients with ARVD/C compared
to RVOT tachycardia patients. We assumed that it would
be worthy to compare these two groups with age and sex
match controls. Nevertheless, we hypothesized that healthy
people should have lower inﬂammatory state rather than
both studied groups.
Ventricular tachycardia is a common clinical feature of
ARVD/C,nomatterofrightventricularcontractilitychanges
evaluating by RVEF as shown our results. This ﬁnding
supports the already known fact that the early “concealed”
phase is characterized by a propensity toward ventricular
tachyarrhythmia and sudden cardiac death (SCD) in the
settingofwell-preservedmorphology,histology,andventric-
ular function [33].
The question of whether the elevation of this inﬂamma-
tory biomarker is the cause or consequence of ventricular
arrhythmia manifestation in the setting of ARVD/C is a
major concern. Our study aimed at determining if VA
causes the elevation of CRP in the setting of ARVD/C. For
this purpose, we analysed all ambulatory or inpatient 12-
leads ECG, 24-h ECG monitoring and storage and ICD
electrograms of patients at the admission. CRP testing was
drawn at the admission prior to any invasive intervention
such as EP study or ICD implantation. Therefore, neither
programmed ventricular pacing nor ICD therapy could
inﬂuence levels of inﬂammatory state of this sample.
We found that CRP level was signiﬁcantly higher when
measured immediately after VT occurrence (<24h). How-
ever our retrospective cross-sectional study design was not
appropriate to establish if this association was a cause or a
consequence. The results suggest that the CRP level may not
be associated with aetiology or pathogenesis of ventricular
tachycardia. Activation of systemic inﬂammation seems to
be the consequence rather than the cause of ventricular
arrhythmia in these patients.
Ourﬁndingssupportthehypothesisthatthereisahigher
level of CRP in ARVD/C patients soon after ventricular
tachycardia and that this probably tends to decrease after the
ventricular tachycardia. However the cause of the elevation
of CRP in these patients and its relation to ventricular
tachycardia are unclear.
4.4. Study Limitations. First, we did not use the nephelomet-
ric technique in assessing highly sensitive C-reactive protein
(hs-CRP) which is about a 10-fold more sensitive than the
immunoturbidimetric assay used in this trial. That was due
to the fact that nephelometric technique was not available
in our centre at the beginning of inclusion. Therefore,
our results are less sensitive. Second, this is a retrospective
observational study with some deﬁciencies in rigorous
establishment of serial timing between blood testing for
CRP concentration and the occurrence of arrhythmic events.
Third, CRP levels have been analyzed in the plasma only and
no correlation with myocardial inﬂammation is given as no
biopsieshavebeentaken.Accordingly,conclusionsaredrawn
fromtheplasmaintothemyocardium.Fourth,atruecontrol
group represented by healthy people matched by age and
sex is lacking. Fifth, our control group could not diagnose
ARVD/C at the moment of the study, but the diagnosis of
idiopathic right ventricular outﬂow tract seems to be an
exclusion diagnosis with the possible disease progression to
ascertaine ARVD/C.
5. Conclusion
This study is the ﬁrst to demonstrate that systemic inﬂam-
mation expressed by high C-reactive protein concentration
is a more active process soon after spontaneous ventricular
arrhythmia in ARVD/C patients, independently of ventricu-
lar rate.6 Cardiology Research and Practice
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